PDF herunterladen
Thromb Haemost
DOI: 10.1055/a-2515-1402
Blood Cells, Inflammation and Infection

Factor VIIa–Antithrombin Complexes are Increased in Asthma: Relation to the Exacerbation-Prone Asthma Phenotype

Stanislawa Bazan-Socha 
1   Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
,
Lucyna Mastalerz
1   Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
,
Agnieszka Cybulska
1   Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
,
Lech Zareba
2   College of Natural Sciences, Institute of Computer Science, University of Rzeszow, Rzeszów, Poland
,
Bogdan Jakiela
1   Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
,
Michal Zabczyk 
3   Department of Thromboembolic Diseases, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
,
Teresa Iwaniec
4   Department of Hematology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
,
Anetta Undas
3   Department of Thromboembolic Diseases, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
5   Centre for Medical Research and Technologies, The St. John Paul II Hospital, Krakow, Poland
› Institutsangaben Funding This project was funded by the Polish National Science Centre (No: DEC-2013/09/B/NZ5/00758).
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints


Abstract

Background Asthma is associated with a prothrombotic state. Plasma factor VIIa–antithrombin complex (FVIIa-AT) concentrations indirectly reflect the interaction of tissue factor (TF) with FVII. Since TF is a key initiator of coagulation in vivo, we hypothesized that FVIIa-AT concentrations are higher in asthma.

Methods In 159 clinically stable adult asthma patients and 62 controls, we determined FVIIa-AT in plasma and analyzed their relation to circulating inflammatory and prothrombotic markers together with the total plasma potential for fibrinolysis (clot lysis time, CLT) and thrombin generation. We recorded clinical outcomes, including asthma exacerbations, during 3-year follow-up.

Results Asthma patients were characterized by 38.5% higher FVIIa-AT (p < 0.001), related to bronchial obstruction (FEV1: r = −0.397, p < 0.001), asthma severity (r = 0.221, p = 0.005), and duration (r = 0.194, p = 0.015) compared to controls. FVIIa-AT showed weak positive associations with C-reactive protein (r = 0.208, p = 0.009), fibrinogen (r = 0.215, p = 0.007), and CLT (r = 0.303, p < 0.001) but not with thrombin generation parameters. In the follow-up (data obtained from 151 patients), we documented 151 severe asthma exacerbations in 51 (33.8%) patients, including 33 (21.9%) with ≥2 such events. Exacerbation-prone asthma phenotype was related to 13.1% higher FVIIa-AT (p = 0.012), along with asthma severity and control (p < 0.003, both). High FVIIa-AT (that is ≥100.1 pmol/L), defined on receiver operating characteristic curves, was linked to exacerbation-prone asthma phenotype (odds ratio 1.85; 95%CI: 1.23–2.80, p = 0.003) and shorter time to first exacerbation (p = 0.023).

Conclusion This study is the first to show that FVIIa-AT concentrations are higher in asthma in relation to its severity and may help identify individuals at risk of the exacerbation-prone asthma phenotype.

Keywords

asthma - coagulation - inflammation - tissue factor - prothrombotic state

Data Availability Statement

The data sets are available from the corresponding author on a reasonable request.


Authors' Contribution

A.C., L.C., and S.B-S. recruited the patients and analyzed clinical data. L.M. and A.U. conceived and designed the study. T.I., B.J., and M.Z. performed the experiments and interpreted the laboratory data. L.Z. did statistical analysis. A.U. and S.B-S. interpreted all data. S.B-S., B.J., and A.U. drafted the manuscript; all the other authors revised it critically. All authors approved the final version of the manuscript and agreed to be responsible for their aspects of the work.


Supplementary Material



Publikationsverlauf

Eingereicht: 09. Oktober 2024

Angenommen: 12. Januar 2025

Accepted Manuscript online:
13. Januar 2025

Artikel online veröffentlicht:
31. Januar 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Global Initiative for Asthma - Global Initiative for Asthma - GINA. Published 2016. Accessed September 26, 2024 at: http://ginasthma.org/
    PubMed
  • 2 Federico MJ, Denlinger LC, Corren J, Szefler SJ, Fuhlbrigge AL. Exacerbation-prone asthma: a biological phenotype or a social construct. J Allergy Clin Immunol Pract 2021; 9 (07) 2627-2634
    CrossrefPubMedSuche in Google Scholar
  • 3 Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy 2009; 39 (02) 193-202
    CrossrefPubMedSuche in Google Scholar
  • 4 Sanak M. Aspirin–induced asthma: a still evolving area of basic and clinical research. Pol Arch Intern Med 2022; 132 (02) 16219
    CrossrefPubMedSuche in Google Scholar
  • 5 Cazzola M, Rogliani P, Ora J, Calzetta L, Matera MG. Asthma and comorbidities: recent advances. Pol Arch Intern Med 2022; 132 (04) 16250
    CrossrefPubMedSuche in Google Scholar
  • 6 Jakiela B, Rebane A, Soja J. et al. Remodeling of bronchial epithelium caused by asthmatic inflammation affects its response to rhinovirus infection. Sci Rep 2021; 11 (01) 12821
    CrossrefPubMedSuche in Google Scholar
  • 7 de Boer JD, Majoor CJ, van 't Veer C, Bel EHD, van der Poll T. Asthma and coagulation. Blood 2012; 119 (14) 3236-3244
    CrossrefPubMedSuche in Google Scholar
  • 8 Salzmann M, Gibler P, Haider P. et al. Neutrophil extracellular traps induce persistent lung tissue damage via thromboinflammation without altering virus resolution in a mouse coronavirus model. J Thromb Haemost 2024; 22 (01) 188-198
    CrossrefPubMedSuche in Google Scholar
  • 9 Kokelj S, Östling J, Fromell K. et al. Activation of the complement and coagulation systems in the small airways in asthma. Respiration 2023; 102 (08) 621-631
    CrossrefPubMedSuche in Google Scholar
  • 10 Chung WS, Lin CL, Chen YF, Ho FM, Hsu WH, Kao CH. Increased stroke risk among adult asthmatic patients. Eur J Clin Invest 2014; 44 (11) 1025-1033
    CrossrefPubMedSuche in Google Scholar
  • 11 Majoor CJ, Kamphuisen PW, Zwinderman AH. et al. Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur Respir J 2013; 42 (03) 655-661
    CrossrefPubMedSuche in Google Scholar
  • 12 Chung WS, Shen TC, Lin CL, Chu YH, Hsu WH, Kao CH. Adult asthmatics increase the risk of acute coronary syndrome: a nationwide population-based cohort study. Eur J Intern Med 2014; 25 (10) 941-945
    CrossrefPubMedSuche in Google Scholar
  • 13 Chung WS, Lin CL, Ho FM. et al. Asthma increases pulmonary thromboembolism risk: a nationwide population cohort study. Eur Respir J 2014; 43 (03) 801-807
    CrossrefPubMedSuche in Google Scholar
  • 14 Wee JH, Park MW, Min C, Byun SH, Park B, Choi HG. Association between asthma and cardiovascular disease. Eur J Clin Invest 2021; 51 (03) e13396
    CrossrefPubMedSuche in Google Scholar
  • 15 Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P. Asthma and comorbid medical illness. Eur Respir J 2011; 38 (01) 42-49
    CrossrefPubMedSuche in Google Scholar
  • 16 Zöller B, Pirouzifard M, Memon AA, Sundquist J, Sundquist K. Risk of pulmonary embolism and deep venous thrombosis in patients with asthma: a nationwide case-control study from Sweden. Eur Respir J 2017; 49 (02) 1601014
    CrossrefPubMedSuche in Google Scholar
  • 17 Bazan-Socha S, Mastalerz L, Cybulska A. et al. Asthma is associated with enhanced thrombin formation and impaired fibrinolysis. Clin Exp Allergy 2016; 46 (07) 932-944
    CrossrefPubMedSuche in Google Scholar
  • 18 Sneeboer MMS, Majoor CJ, de Kievit A. et al. Prothrombotic state in patients with severe and prednisolone-dependent asthma. J Allergy Clin Immunol 2016; 137 (06) 1727-1732
    CrossrefPubMedSuche in Google Scholar
  • 19 Tomasiak-Lozowska MM, Misztal T, Rusak T, Branska-Januszewska J, Bodzenta-Lukaszyk A, Tomasiak M. Asthma is associated with reduced fibrinolytic activity, abnormal clot architecture, and decreased clot retraction rate. Allergy 2017; 72 (02) 314-319
    CrossrefPubMedSuche in Google Scholar
  • 20 Bazan-Socha S, Mastalerz L, Cybulska A. et al. Prothrombotic state in asthma is related to increased levels of inflammatory cytokines, IL-6 and TNFα, in peripheral blood. Inflammation 2017; 40 (04) 1225-1235
    CrossrefPubMedSuche in Google Scholar
  • 21 Bazan-Socha S, Mastalerz L, Cybulska A. et al. Impaired fibrinolysis and lower levels of plasma α2-macroglobulin are associated with an increased risk of severe asthma exacerbations. Sci Rep 2017; 7 (01) 11014
    CrossrefPubMedSuche in Google Scholar
  • 22 Grover SP, Mackman N. Tissue factor. Arterioscler Thromb Vasc Biol 2018; 38 (04) 709-725
    CrossrefPubMedSuche in Google Scholar
  • 23 Rezaie AR, Giri H. Anticoagulant and signaling functions of antithrombin. J Thromb Haemost 2020; 18 (12) 3142-3153
    CrossrefPubMedSuche in Google Scholar
  • 24 Spiezia L, Campello E, Valle FD, Woodhams B, Simioni P. Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation. Clin Chem Lab Med 2017; 55 (04) 484-488
    CrossrefPubMedSuche in Google Scholar
  • 25 Silveira A, Scanavini D, Boquist S. et al. Relationships of plasma factor VIIa-antithrombin complexes to manifest and future cardiovascular disease. Thromb Res 2012; 130 (02) 221-225
    CrossrefPubMedSuche in Google Scholar
  • 26 Paszek E, Pociask E, Ząbczyk M, Butenas S, Undas A. Activated factor XI is associated with increased factor VIIa-antithrombin complexes in stable coronary artery disease: impact on cardiovascular outcomes. Eur J Clin Invest 2022; 52 (12) e13857
    CrossrefPubMedSuche in Google Scholar
  • 27 Martinelli N, Girelli D, Baroni M. et al. Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study. J Thromb Haemost 2016; 14 (04) 655-666
    CrossrefPubMedSuche in Google Scholar
  • 28 Moruzzi S, Castagna A, Spizzo M. et al. Activated factor VII-antithrombin complex, a biomarker of tissue factor-related pathways in different clinical settings: a narrative review from cardiovascular diseases to cancer. Diagnostics (Basel) 2024; 14 (16) 1711
    CrossrefPubMedSuche in Google Scholar
  • 29 Reddel HK, Taylor DR, Bateman ED. et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180 (01) 59-99
    CrossrefPubMedSuche in Google Scholar
  • 30 Kremers RMW, Peters TC, Wagenvoord RJ, Hemker HC. The balance of pro- and anticoagulant processes underlying thrombin generation. J Thromb Haemost 2015; 13 (03) 437-447
    CrossrefPubMedSuche in Google Scholar
  • 31 Cates CJ, Lasserson TJ. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev 2009; 2009 (01) CD007085
    PubMedSuche in Google Scholar
  • 32 Marcos-Jubilar M, Lecumberri R, Páramo JA. Immunothrombosis: molecular aspects and new therapeutic perspectives. J Clin Med 2023; 12 (04) 1399
    CrossrefPubMedSuche in Google Scholar
  • 33 Pankiw-Bembenek O, Zalewski J, Goralczyk T, Undas A. A history of early stent thrombosis is associated with prolonged clot lysis time. Thromb Haemost 2012; 107 (03) 513-520
    Thieme ConnectPubMedSuche in Google Scholar
  • 34 Ząbczyk M, Undas A. Plasma fibrin clot structure and thromboembolism: clinical implications. Pol Arch Intern Med 2017; 127 (12) 873-881
    CrossrefPubMedSuche in Google Scholar
  • 35 Meltzer ME, Doggen CJM, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35 (05) 468-477
    Thieme ConnectPubMedSuche in Google Scholar
  • 36 Undas A, Ariëns RAS. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31 (12) e88-e99
    CrossrefPubMedSuche in Google Scholar
  • 37 Castagna A, Senna G, Argentino G, Caminati M, Friso S, Martinelli N. Asthma and coagulation: a (seemingly) strange couple and its pathophysiological and clinical implications. J Allergy Hypersensitivity Dis 2024; 2: 100012
    CrossrefPubMedSuche in Google Scholar
  • 38 Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol 2023; 20 (04) 248-262
    CrossrefPubMedSuche in Google Scholar
  • 39 Isada A, Konno S, Hizawa N. et al. A functional polymorphism (-603A –> G) in the tissue factor gene promoter is associated with adult-onset asthma. J Hum Genet 2010; 55 (03) 167-174
    CrossrefPubMedSuche in Google Scholar
  • 40 Isermann B. Homeostatic effects of coagulation protease-dependent signaling and protease activated receptors. J Thromb Haemost 2017; 15 (07) 1273-1284
    CrossrefPubMedSuche in Google Scholar
  • 41 Sokolova E, Reiser G. A novel therapeutic target in various lung diseases: airway proteases and protease-activated receptors. Pharmacol Ther 2007; 115 (01) 70-83
    CrossrefPubMedSuche in Google Scholar
  • 42 Kim HJ, Lee SH, Jeong S, Hong SJ. Protease-activated receptors 2-antagonist suppresses asthma by inhibiting reactive oxygen species—thymic stromal lymphopoietin inflammation and epithelial tight junction degradation. Allergy Asthma Immunol Res 2019; 11 (04) 560-571
    CrossrefPubMedSuche in Google Scholar
  • 43 Gandhi VD, Shrestha Palikhe N, Vliagoftis H. Protease-activated receptor-2: role in asthma pathogenesis and utility as a biomarker of disease severity. Front Med (Lausanne) 2022; 9: 954990
    CrossrefPubMedSuche in Google Scholar
  • 44 Jiang H, Nechipurenko DY, Panteleev MA, Xu K, Qiao J. Redox regulation of platelet function and thrombosis. J Thromb Haemost 2024; 22 (06) 1550-1557
    CrossrefPubMedSuche in Google Scholar
  • 45 Bazan-Socha S, Jakiela B, Zuk J. et al. Interactions via α2β1 cell integrin may protect against the progression of airway structural changes in asthma. Int J Mol Sci 2021; 22 (12) 6315
    CrossrefPubMedSuche in Google Scholar
  • 46 Wu H, Wang Y, Zhang Y. et al. Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress. Redox Biol 2020; 32: 101500
    CrossrefPubMedSuche in Google Scholar
  • 47 Bazan-Socha S, Wójcik K, Olchawa M. et al. Increased oxidative stress in asthma-relation to inflammatory blood and lung biomarkers and airway remodeling indices. Biomedicines 2022; 10 (07) 1499
    CrossrefPubMedSuche in Google Scholar
  • 48 Mitchel JA, Antoniak S, Lee JH. et al. IL-13 augments compressive stress-induced tissue factor expression in human airway epithelial cells. Am J Respir Cell Mol Biol 2016; 54 (04) 524-531
    CrossrefPubMedSuche in Google Scholar
  • 49 Moffatt JD, Page CP, Laurent GJ. Shooting for PARs in lung diseases. Curr Opin Pharmacol 2004; 4 (03) 221-229
    CrossrefPubMedSuche in Google Scholar
  • 50 Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005; 105 (07) 2764-2770
    CrossrefPubMedSuche in Google Scholar